Effectiveness of Self-adjusted Phosphate Binder Dose According to Dietary Phosphate Content Method In Improving Hyperphosphatemia Among Hemodialysis Patients

Serum phosphate level control is a major goal in the management of hyperphosphatemia among end stage kidney disease patients. This study aimed to evaluate the effectiveness of self-adjusted phosphate binder dose according to dietary phosphate content method (SPB method) in optimizing the phosphate level among hemodialysis patients. This was a randomized controlled study conducted from September 2015 to October 2016 which involved eight hemodialysis centers in Penang, Malaysia. Ninety-eight hemodialysis patients who had serum phosphate level more than 1.8 mmol/L were recruited and randomly assigned to intervention and standard group. All patients underwent a standard low phosphate counseling. The 49 patients in intervention group underwent an additional counseling on how to adjust the calcium carbonate tablet dose based on their food intake with the help of a booklet. Meanwhile, the calcium carbonate dose was fixed to the meals among the patients in standard group. The change in serum phosphate levels in both groups at baseline, month-3, month-6 and month-9 were recorded. The phosphate level at baseline for intervention (2.15±0.22 mmol/L) and standard (2.22±0.27 mmol/L) group were not differed significantly (p = 0.19). The intervention group showed significant lower phosphate level compared to standard group (month-3: 1.68±0.43 mmol/L versus 2.10±0.39 mmol/L; month-6: 1.58±0.34 mmol/L versus 2.07±0.38 mmol/L; month-9: 1.54±0.36 mmol/L versus 1.96±0.33 mmol/L; P < 0.001). The SPB method demonstrated significant greater serum phosphate level reduction than the fixed-dose method. This new method in consuming phosphate binder dose should be introduced among the hemodialysis patients.

PDF

___

Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P. Phosphate control in dialysis. Int J Nephrol Renovasc Dis 2013;6: 193-205.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15: 2208-2218.

Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.

Shaman AM, Kowalski SR. Hyperphosphatemia management in patients with chronic kidney disease. Saudi Pharm J 2016; 24: 494-505.

Nadkarni GN, Uribarri J. Phosphorus and the kidney: What is known and what is needed. Adv Nutr 2014; 5: 98-103.

Kalantar-Zadeh K. Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence 2013; 7: 379-390.

Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis. (5th ed). Philadelphia: Wolters Kluwer Health, 2015.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76: 1-130.

Kuhlmann MK. Management of hyperphosphatemia. Hemodialysis Int 2006; 10: 338-345.

Kuhlmann MK, Hoechst S, Landthaler I. Patient empowerment in the management of hyperphosphatemia. Int J Artif Organs 2007; 30: 1008-1013.

Uribarri J. Phosphorus additives in food and their effect in dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1290-122.

Karalis M, Murphy-Gutekunst L. Patient education. Enhanced foods: hidden phosphorus and sodium in foods commonly eaten. J Ren Nutr 2006; 16: 79-81.

Noori N, Sims JJ, Kopple J, et al. Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iran J Kidney Dis 2010; 4: 89-100.

Cupisti A, Kalantar-Zadeh K. Management of natural and added dietary phosphorus burden in kidney disease. Semin Nephrol 2013; 33: 180-190.

Suresh KP, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci 2012; 5: 7-13.

Tee ES, Azudin MN, Idris K. Nutrient composition of Malaysian foods. (4th ed). Kuala Lumpur: Institute for Medical Research, 1997.

Singapore Health Promotion Board. Food Composition Guide Singapore. Singapore: Health Promotion Board, 2003.

Ma Y, Olendzki BC, Pagoto SL, et al. Number of 24-hour diet recalls needed to estimate energy intake. Ann Epidemiol 2009; 19: 553-559.

Bross R, Noori N, Kovesdy CP, et al. Dietary assessment of individuals with chronic kidney disease. Semin Dial 2010; 23: 359-364.

Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.

Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.

Ahlenstiel T, Pape L, Ehrich JH, Kuhlmann MK. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3241-3249.

Zimmerman DL, McCormick B. Development of a 'Phosphate Counting Program' on an iTouch to simplify self-management of dietary phosphate by patients with end stage renal disease (ESRD) treated with peritoneal dialysis. Ottawa: Ottawa Hospital Research Institute, 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01643486 (accessed 19 June 2018).

Hayashi A, Yamaguchi S, Waki K, et al. Testing the feasibility and usability of a novel smartphone-based self-management support system for dialysis patients: A pilot study. JMIR Res Protoc 2017; 6: 63.

Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009; 24: 3168-3174.

Inaguma D, Koide S, Takahashi K, et al. Relationship between serum calcium level at dialysis initiation and subsequent prognosis. Ren Replace Ther 2017; 3: 2.

Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83: 959-966.

Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-1277.

Leung S, McCormick B, Wagner J, et al. Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study. BMC Nephrol 2015; 16: 205.

Sridhar NR, Josyula S. Hypoalbuminemia in hemodialyzed end stage renal disease patients: risk factors and relationships - a 2 year single center study. BMC Nephrol 2013; 14: 242.

Phelan PJ, O'Kelly P, Walshe JJ, Conlon PJ. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail 2008; 30: 423-429.

National Renal Registry. 22nd report of the Malaysian dialysis and transplant registry 2014.